Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?

Journal of clinical lipidology - 1 Jan 2000

Othman Alaa, Benghozi Renee, Alecu Irina, Wei Yu, Niesor Eric, von Eckardstein Arnold, Hornemann Thorsten

Abstract excerpt

BACKGROUND: The condensation of palmitoyl-CoA and L-Serine is the first step in the de novo formation of sphingolipids and catalyzed by the serine-palmitoyltransferase (SPT). Besides other acyl-CoAs the SPT can also metabolize L-alanine and glycine, which forms an atypical category of neurotoxic 1-deoxy-sphingolipids (1-deoxySL). Several mutations in SPT are associated with pathologically increased 1-deoxySL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Diabetic Neuropathies

Share to Hereditary Sensory and Autonomic Neuropathies

Share to Mutation

Share to Niacin

Share to Sphingolipids

Share to Triglycerides

Source

Identifiers

PMID: 26228675
DOI: 10.1016/j.jacl.2015.03.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?PMID 26228675Read ↗

Cytotoxic 1-deoxysphingolipids are metabolized by a cytochrome P450-dependent pathway.Semantic proximity Read ↗

1-Deoxysphingolipids Encountered Exogenously and Made de Novo: Dangerous Mysteries inside an Enigma.Semantic proximity Read ↗

Divergent amino acid and sphingolipid metabolism in patients with inherited neuro-retinal diseaseSemantic proximity Read ↗

Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids.Semantic proximity Read ↗

CYP4F2-mediated ω-hydroxylation of 1-deoxysphingolipids reveals a new hepatic detoxification pathwaySemantic proximity Read ↗

Aberrant DEGS1 sphingolipid metabolism impairs central and peripheral nervous system function in humansSemantic proximity Read ↗

Metabolic Origins of Neurotoxic 1-deoxySphingolipids in Type 2 DiabetesSemantic proximity Read ↗

Clinical and metabolic consequences of L-serine supplementation in hereditary sensory and autonomic neuropathy type 1C.Semantic proximity Read ↗

Sphingolipid remodelling in SPT-related neuropathiesSemantic proximity Read ↗

Oral l-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1Semantic proximity Read ↗

Hepatic serine and lipid metabolism drive diabetic peripheral neuropathySemantic proximity Read ↗

1-Deoxysphingolipids Require Very-Long-Chain Ceramide Synthesis to Induce ER Stress and NeurotoxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.